Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | ABCB1 | P08183 | 10/20 | 0.55 |
| ▸ | ATM | Q13315 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14468904 | 0.84 | USP2 (0.60) | ABCB1POLBALDH1A1TSHR | |
| SCHEMBL1105465 | 0.84 | USP2 (0.60) | ABCB1POLBALDH1A1TSHR | |
| SCHEMBL6569639 | 0.83 | PKM (0.51) | PKMMEN1KMT2AABCB1ATM | |
| SCHEMBL28123602 | 0.82 | PKM (0.56) | PKMMEN1KMT2AABCB1ATM | |
| SCHEMBL4632137 | 0.78 | PKM (0.52) | PKMMEN1KMT2AABCB1ATM | |
| SCHEMBL13869703 | 0.78 | PKM (0.49) | PKMMEN1KMT2AABCB1ATM | |
| SCHEMBL68147 | 0.77 | KMT2A (0.64) | MEN1KMT2AABCB1ATMCYP2D6 | |
| SCHEMBL5698940 | 0.76 | MEN1 (0.52) | PKMMEN1KMT2AABCB1ATM | |
| SCHEMBL7526130 | 0.76 | ABCB1 (0.49) | PKMMEN1KMT2AABCB1ATM | |
| SCHEMBL20027940 | 0.75 | KMT2A (0.60) | MEN1KMT2AABCB1ATMCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180186783-A1 | INHIBITORS OF PROTEIN KINASES | ALEXION PHARMACEUTICALS, INC. | 2018-07-05 | — | — | US | disclosed |
| US-9868729-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9359375-B2 | Benzamides and nicotinamides as Syk modulators | PORTOLA PHARMACEUTICALS, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20150353495-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | ALEXION PHARMACEUTICALS, INC. | 2015-12-10 | — | — | US | disclosed |
| US-9139581-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20150094298-A1 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. | 2015-04-02 | — | — | US | disclosed |
| US-20150038492-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | ALEXION PHARMACEUTICALS, INC. | 2015-02-05 | — | — | US | disclosed |
| US-8937070-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-01-20 | — | — | US | disclosed |
| US-8846928-B2 | Benzamides and nicotinamides as Syk modulators | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140213583-A1 | PI3K Inhibitor for Use in the Treatment of Bone Cancer or for Preventing Metastatic Dissemination Primary Cancer Cells into the Bone | NOVARTIS AG (CH) | 2014-07-31 | — | — | US | disclosed |
| US-8138339-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20100249126-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3-KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-7767669-B2 | Small molecule PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-08-03 | — | — | US | disclosed |
| US-20090318407-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090298823-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090074886-A1 | GSK-3 INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS INC. | 2009-03-19 | — | — | US | disclosed |
| US-7504405-B2 | Mitotic kinesin inhibitors | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20090060912-A1 | SMALL MOLECULE PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | CHIRON CORPORATION (US) | 2009-03-05 | — | — | US | disclosed |
| US-20080249112-A1 | Mitotic Kinesin Inhibitors | CHIRON CORPORATION (US) | 2008-10-09 | — | — | US | disclosed |
| US-7423148-B2 | Small molecule PI 3-kinase inhibitors and methods of their use | CHIRON CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318407-A1 | Inhibitors of protein kinases | SYK, BTK, JAK1 | PKM 783/4885MEN1 2865/4885KMT2A 1876/4885 |
| US-20140213583-A1 | PI3K Inhibitor for Use in the Treatment of Bone Cancer or for Preventing Metastatic Dissemination Primary Cancer Cells into the Bone | PIK3CA, AKT3, AKT2 | PKM 2175/4885MEN1 487/4885KMT2A 2222/4885 |
| US-20090074886-A1 | GSK-3 INHIBITORS | GSK3B, GSK3A, GSKIP | PKM 562/4885MEN1 2112/4885KMT2A 2311/4885 |
| US-20100249126-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3-KINASE INHIBITORS | PIK3CA, PI4KA, PI4KB | PKM 759/4885MEN1 2431/4885KMT2A 2616/4885 |
| US-20090060912-A1 | SMALL MOLECULE PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | PI4KB, AKT3, PI4KA | PKM 408/4885MEN1 1863/4885KMT2A 2719/4885 |
| US-20180186783-A1 | INHIBITORS OF PROTEIN KINASES | SYK, BTK, JAK1 | PKM 783/4885MEN1 2865/4885KMT2A 1876/4885 |
| US-20150353495-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | JAK2, JAK1, NADK | PKM 590/4885MEN1 2476/4885KMT2A 1713/4885 |
| US-20080249112-A1 | Mitotic Kinesin Inhibitors | KIF5B, KIF2C, KIFC1 | PKM 385/4885MEN1 1408/4885KMT2A 473/4885 |
| US-20090298823-A1 | Inhibitors of protein kinases | SYK, BTK, JAK2 | PKM 741/4885MEN1 3367/4885KMT2A 1671/4885 |
| US-20150038492-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | SYK, BTK, NADK | PKM 665/4885MEN1 3407/4885KMT2A 1192/4885 |
| US-20150094298-A1 | INHIBITORS OF PROTEIN KINASES | SYK, BTK, JAK1 | PKM 783/4885MEN1 2865/4885KMT2A 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.